Besides the anti-TNFα therapies approved in the last 20 years for the treatment of SpA patients (45–47), with proved efficacy also for the treatment of extraarticular manifestations such as uveitis (RAPID-axSpA ClinicalTrials.gov Identifier: NCT01087762) (48), biosimilars of TNFα inhibitors have become increasingly used, and observational studies of biologics-naïve patients with SpA have shown similar response and safety in patients treated with originators versus biosimilars, indicating comparable effects in clinical practice (49). Here, TNF is linked to uveitis.